Repatha Manufacturer Copay Program: How to Cut Your Out-of-Pocket Cost in 2026

Why Repatha Costs So Much at the Pharmacy Counter

Repatha (evolocumab) is a fully human monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein the liver uses to clear LDL receptors from the cell surface. By inhibiting PCSK9, evolocumab allows more LDL receptors to remain active, pulling LDL cholesterol out of the bloodstream. The drug is manufactured by Amgen and delivered as a subcutaneous injection every two weeks (140 mg) or once monthly (420 mg).

Biologic drugs like evolocumab are expensive to produce. A single month of Repatha carries an average wholesale acquisition cost near $580. That figure can climb above $700 at certain retail pharmacies, depending on your region. Even with insurance, many patients face steep coinsurance charges on specialty-tier medications. A 2023 analysis published in JAMA Network Open found that median annual out-of-pocket spending for PCSK9 inhibitor users on commercial plans was $452, but patients on high-deductible plans paid considerably more before reaching their deductible [1]. The 2016 net price reduction by Amgen (approximately 60% from the original $14,523 annual list) helped, yet the remaining cost still blocks access for many patients who meet clinical criteria for therapy.

This gap between clinical need and affordability is exactly what the manufacturer copay program is designed to close.

How the Amgen Repatha Copay Card Works

The Repatha copay card is Amgen's primary tool for lowering the price commercially insured patients pay at the pharmacy. Eligible patients can pay as little as $5 per monthly prescription fill. Amgen covers the difference between your insurance plan's required copay or coinsurance and that $5 floor, up to a maximum benefit of $17,000 per calendar year.

Enrollment takes roughly five minutes. You can sign up online at the official Amgen Repatha support site, by calling the Repatha support line, or through your prescribing physician's office. Once enrolled, you receive a digital or physical copay card that the pharmacy processes as a secondary payer at the point of sale. There is no separate reimbursement claim to file.

The card resets each January 1. You must re-enroll annually to continue receiving the benefit. Amgen reserves the right to modify program terms at any time, so confirming current details before each renewal is worth the two minutes it takes. Program terms as of early 2026 remain consistent with this structure, but always verify directly with Amgen.

Eligibility Requirements and Exclusions

The copay card is available to U.S. residents aged 18 or older who have commercial (private) health insurance that covers Repatha, even partially. Patients must have a valid prescription from a licensed provider for an FDA-approved indication.

The program excludes patients enrolled in Medicare Part D, Medicaid, Tricare, the VA health system, or any other federal or state-funded healthcare program. This exclusion is mandated by the federal Anti-Kickback Statute and the OIG guidance on manufacturer copay assistance. Patients dually eligible for Medicare and a commercial plan do not qualify.

If you lose commercial coverage mid-year (for example, by aging into Medicare), the copay benefit ends on the date your commercial coverage terminates.

What the FOURIER Trial Tells Us About the Clinical Stakes

Cost assistance programs exist because PCSK9 inhibitors have demonstrated measurable cardiovascular benefit, and nonadherence due to cost undermines those outcomes. The FOURIER trial (N=27,564), published in the New England Journal of Medicine in 2017, randomized patients with established atherosclerotic cardiovascular disease to evolocumab or placebo on top of statin therapy. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [2].

LDL cholesterol dropped by a median of 59%, from 92 mg/dL to 30 mg/dL. The benefit was consistent across prespecified subgroups, including patients with diabetes, those with baseline LDL above 100 mg/dL, and patients already on high-intensity statins.

A subsequent FOURIER open-label extension analysis, presented at the 2022 American Heart Association Scientific Sessions, showed that the cardiovascular benefit of evolocumab persisted and appeared to grow over a median of 5 years, with a 20% reduction in cardiovascular death, MI, or stroke (HR 0.80; 95% CI 0.68 to 0.93) [3]. The safety profile remained stable over that period.

These results matter for cost discussions because stopping the drug erases the benefit. A 2019 analysis in Circulation demonstrated that patients who discontinued PCSK9 inhibitor therapy experienced an LDL rebound to pre-treatment levels within 4 weeks, and the cardiovascular risk reduction was lost [4].

Step-by-Step: Activating Your Repatha Copay Card

Getting the card working requires coordination between you, your prescriber, and your pharmacy. Here is the sequence that avoids the most common delays.

1. Confirm insurance coverage. Before applying for the copay card, call the number on the back of your insurance card and ask whether Repatha is on formulary. If it requires prior authorization (PA), your prescriber's office will need to submit clinical documentation. Most commercial plans require PA for PCSK9 inhibitors. The 2022 ACC Expert Consensus Decision Pathway recommends documenting statin intolerance or inadequate LDL response on maximally tolerated statin therapy as part of the PA submission [5].

2. Enroll in the copay program. Visit the Amgen Repatha patient support portal or call the support line. You will need your insurance information, prescriber's name, and the pharmacy where you plan to fill.

3. Receive your copay card. Digital cards arrive immediately by email. Physical cards take 7 to 10 business days.

4. Present the card at your pharmacy. The pharmacist runs your insurance first, then applies the copay card to cover the remaining patient responsibility. If your plan uses a specialty pharmacy, provide the copay card information when the specialty pharmacy calls to arrange shipment.

5. Track your benefit. You can monitor how much of the $17,000 annual cap you have used through the Amgen support portal. A patient using the card for 12 monthly fills at a plan coinsurance of $150 per fill would use $1,740 of the annual cap (12 x [$150 minus $5]).

When Insurance Denies Coverage: The Prior Authorization Process

Insurance denial is the single largest barrier to starting Repatha. A retrospective cohort study published in JAMA Cardiology in 2017 found that only 47% of initial prior authorization requests for PCSK9 inhibitors were approved, with approval rates climbing to 75% after appeal [6]. Those numbers have improved since formulary coverage expanded after the 2018 and 2019 net price reductions, but denials remain common.

The most frequent denial reason is insufficient documentation of statin intolerance or failure. Plans typically require evidence that the patient tried at least two statins at appropriate doses, or documentation of confirmed statin-associated muscle symptoms using a validated tool like the statin myalgia clinical index.

If your PA is denied, you have the right to appeal. The appeal should include lab results showing persistent LDL elevation despite maximally tolerated therapy, the specific FDA-approved indication being treated, and any relevant cardiovascular history. Your prescriber can also request a peer-to-peer review with the insurance company's medical director.

The Amgen patient support program includes a dedicated team that helps with prior authorization paperwork and appeals. This is a separate service from the copay card itself.

Alternatives if You Do Not Qualify for the Copay Card

Not everyone carries commercial insurance. Medicare patients, the uninsured, and those on government programs need different pathways.

Amgen Safety Net Foundation. This is Amgen's patient assistance program (PAP) for patients who are uninsured or underinsured and meet income eligibility criteria (generally household income at or below 400% of the federal poverty level). Qualifying patients receive Repatha at no cost. The application requires income documentation and a prescriber signature. Processing takes approximately 4 to 6 weeks.

Medicare Part D Extra Help. Patients with limited income and resources may qualify for the Medicare Part D Low-Income Subsidy (LIS, also called "Extra Help"), which reduces copays on covered Part D drugs to $0 to $11.20 per fill in 2026. If your Part D plan covers Repatha, the LIS benefit can substantially lower your cost.

State Pharmaceutical Assistance Programs (SPAPs). Several states operate programs that supplement Medicare Part D coverage. Eligibility and benefit structures vary by state.

Formulary alternatives. Alirocumab (Praluent), the other approved PCSK9 inhibitor, has its own copay assistance program and may be on a preferred tier with certain plans. Inclisiran (Leqvio), a small interfering RNA targeting PCSK9 mRNA administered twice yearly by a healthcare provider, received FDA approval in 2021 and may be covered differently because it is administered in-office rather than self-injected [7]. The 2020 ACC/AHA guidelines on the management of blood cholesterol do not preferentially recommend one PCSK9-targeting therapy over another for most patients [8].

Bempedoic acid. For patients whose primary barrier is LDL reduction (not specifically the cardiovascular event reduction demonstrated with PCSK9 inhibitors), bempedoic acid (Nexletol) is an oral, non-statin LDL-lowering drug. The CLEAR Outcomes trial (N=13,970) showed a 13% reduction in major adverse cardiovascular events with bempedoic acid in statin-intolerant patients [9]. Its monthly cost is substantially lower than evolocumab.

How Much You Can Realistically Expect to Pay

Your actual out-of-pocket cost depends on your insurance plan design. Here are three common scenarios.

Scenario 1: Commercial PPO, specialty tier, 30% coinsurance. Without the copay card, you would pay roughly $174 per month (30% of $580). With the card, you pay $5. Annual savings: approximately $2,028.

Scenario 2: High-deductible health plan (HDHP), $3,000 deductible. You pay full price ($580/month) until you meet the deductible, then your coinsurance kicks in. The copay card applies only to the coinsurance portion after the deductible is met. During the deductible phase, you pay the full negotiated rate. Some HDHPs classify PCSK9 inhibitors as preventive after the ASCVD indication, which may waive the deductible. Check with your plan.

Scenario 3: Medicare Part D. The copay card does not apply. In the catastrophic coverage phase (after $8,000 in true out-of-pocket spending in 2026 under the Inflation Reduction Act cap), your cost drops to $0 for covered drugs. The $2,000 annual out-of-pocket cap introduced by the IRA in 2025 may apply to Repatha if your Part D plan covers it [10].

Keeping Your Cost Low Over the Long Term

Copay programs are not permanent entitlements. Programs change terms, and insurance formularies shift annually during open enrollment. Three practices help maintain affordable access year over year.

First, re-enroll in the copay program before January each year. Set a calendar reminder for December.

Second, review your insurance plan's formulary during open enrollment. If your current plan moves Repatha to a higher tier or removes it, switching plans may restore favorable coverage.

Third, ask your prescriber about dose optimization. The 2022 ACC Expert Consensus pathway notes that some patients achieve target LDL levels on evolocumab 140 mg every two weeks in combination with a statin, while others require the 420 mg monthly dose [5]. If your clinical response allows, discuss whether your current dosing schedule is the most cost-effective option.

The 2018 AHA/ACC cholesterol guideline update sets an LDL threshold of 70 mg/dL for very high-risk ASCVD patients and considers adding a PCSK9 inhibitor when LDL remains above that target on maximally tolerated statin plus ezetimibe [8]. Reaching and maintaining that target is the clinical goal. The copay card is the financial tool that keeps you on track.